Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Biologics (ADMA) Stock Price & Analysis
2,327 Followers
ADMA Stock Chart & Stats
Day’s Range$6.1 - $6.29
52-Week Range― - ―
Previous Close$6.2
Volume3.41M
Average Volume (3M)N/A
Market Cap
$1.44B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.50Price Target Upside35.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ADMA Biologics News
PremiumCompany Announcements
Kaitlin Kestenberg Promoted to COO at ADMA Biologics
PremiumCompany Announcements
ADMA Biologics Enhances Executive Compensation and Seeks New CFO
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's strong execution and continued improvements in gross margin are expected to lead to net profits surpassing $100 million over the next two years.
Market OpportunityRecent momentum does not factor possible market share slippage from Grifols which could represent a potential boon for others.
Product DemandDemand for ASCENIV 'Rare Vintage Blend' continues to outpace supply, leading to a raised price target.
Bears Say
Financial PerformanceADMA recorded a net loss this quarter, primarily due to an accounting loss due to extinguishment of debt.
Product Uptake RisksRisks include slower-than-anticipated uptake for ADMA's plasma-derived protein products.
Supply Chain RisksRisks include inability to establish more sources of plasma to address future demand.
---
Ownership Overview
17.96% Insiders
15.84% Mutual Funds
18.00% Other Institutional Investors
48.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
Currently, no data Available
What is ADMA Biologics’s market cap?
Currently, no data Available
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Feb 28, 2024. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of $0.025 by -$0.105.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is $0.06.
How many shares outstanding does ADMA Biologics have?
Currently, no data Available
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of -$0.08 in its last earnings report, missing expectations of $0.025. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
---
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (35.57% Upside)
$8.50 (35.57% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $9.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.83%
12-Months-Change
Fundamentals
Return on Equity
-19.67%
Trailing 12-Months
Asset Growth
-5.53%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
---
ADMA Earnings Call
Q4 2024
0:00 / 0:00
---
ADMA Stock 12 Months Forecast
Average Price Target
$8.50
▲(35.57% Upside)
Technical Analysis
Best Analysts Covering ADMA
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+44.96%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +44.96% per trade.
---